Cargando…

Outcome of Immediate Dose Optimization of Infliximab in Inflammatory Bowel Disease Patients

Detalles Bibliográficos
Autores principales:	Bacsur, Péter, Farkas, Klaudia, Molnar, Tamás
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228885/ https://www.ncbi.nlm.nih.gov/pubmed/34792132 http://dx.doi.org/10.1093/ecco-jcc/jjab207

Ejemplares similares

Area of the IBD Disk Correlated Strongly with Disease Activity Compared with the Conventionally Used IBD Disk Score
por: Bacsur, Péter, et al.
Publicado: (2021)

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease
por: Bor, Renáta, et al.
Publicado: (2017)

Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls
por: Bacsur, Péter, et al.
Publicado: (2023)

Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination
por: Resál, Tamás, et al.
Publicado: (2023)

Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?
por: Resál, Tamás, et al.
Publicado: (2021)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease
por: Piester, Travis, et al.
Publicado: (2018)

Still the Joker in the Pack: When to Take Out Cyclosporine in the Game?
por: Resál, Tamás, et al.
Publicado: (2021)

Does inflammatory bowel disease have different characteristics according to stage of adolescence?
por: Szántó, Kata Judit, et al.
Publicado: (2021)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

The optimal time to perform an ophthalmic examination of patients with inflammatory bowel disease
por: Biancardi, Ana Luiza, et al.
Publicado: (2019)

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
por: Gonczi, Lorant, et al.
Publicado: (2017)

Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic
por: McGoran, John, et al.
Publicado: (2021)

Inflammatory bowel disease of the lung: The role of infliximab?()
por: Hayek, Adam J., et al.
Publicado: (2015)

Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease
por: Hellmann, Jennifer, et al.
Publicado: (2021)

Psychological characteristics of patients with inflammatory bowel disease during the first wave of COVID-19
por: Dávid, Anett, et al.
Publicado: (2023)

Tremor in Patients with Inflammatory Bowel Disease
por: De Oliveira, Gisele R., et al.
Publicado: (2013)

Infliximab as rescue therapy in refractory Kawasaki disease
por: Rodríguez-González, Moisés, et al.
Publicado: (2014)

Immunosuppressive regimens and outcomes of inflammatory bowel disease patients requiring kidney transplantation
por: Singh, Urvashi, et al.
Publicado: (2022)

Management of inflammatory bowel disease in poor responders to infliximab
por: Guerra, Iván, et al.
Publicado: (2014)

Specific T-Cell Subsets Can Predict the Efficacy of Anti-TNF Treatment in Inflammatory Bowel Diseases
por: Dulic, Sonja, et al.
Publicado: (2020)

Inflammatory bowel disease induced by bimekizumab
por: Wietrzykowska-Grishanovich, Dominika, et al.
Publicado: (2022)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases
por: Kantasiripitak, Wannee, et al.
Publicado: (2022)

Posterior Reversible Encephalopathy Syndrome in a Patient With Crohn’s Disease on Infliximab
por: Chow, Stephen, et al.
Publicado: (2016)

Demodicosis as an opportunistic infection in a patient with Crohn’s disease treated with infliximab
por: Niedźwiedź, Michał, et al.
Publicado: (2022)

Alterations of pulmonary function in patients with inflammatory bowel diseases
por: Al-Mendalawi, Mahmood Dhahir
Publicado: (2017)

The Influence of Nutrition on Intestinal Permeability and the Microbiome in Health and Disease
por: Inczefi, Orsolya, et al.
Publicado: (2022)

Familial inflammatory bowel diseases in Northwest Greece
por: Katsanos, Konstantinos H., et al.
Publicado: (2015)

Inflammatory Bowel Disease and the Risk of Herpes Zoster
por: Lai, Shih-Wei
Publicado: (2019)

Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease
por: Kolho, Kaija-Leena
Publicado: (2021)

Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation
por: Van Stappen, Thomas, et al.
Publicado: (2016)

Infliximab-Associated Acneiform Eruption in a Patient With Inflammatory Bowel Disease
por: Khatana, Usman Feroze, et al.
Publicado: (2021)

Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease
por: Curci, Debora, et al.
Publicado: (2021)

Acute submandibular sialadenitis in a patient with Crohn's disease being treated with infliximab()
por: Blasco Patiño, Felipe, et al.
Publicado: (2021)

Behçet's syndrome treated with infliximab, which caused a palmoplantar pustulosis, subsequently maintained on low-dose etanercept
por: Tresh, Amani, et al.
Publicado: (2012)

Comment on “Prevalence of Anxiety and Depression in Patients with Inflammatory Bowel Disease”
por: Lai, Wenwen, et al.
Publicado: (2018)

Working Together to Meet the Needs of Patients With Inflammatory Bowel Diseases
por: Brenner, Erica J., et al.
Publicado: (2021)

Urotensin II level is elevated in inflammatory bowel disease patients
por: Zhang, Yan, et al.
Publicado: (2022)

Vedolizumab Is Safe in Elderly Veteran Patients With Inflammatory Bowel Disease
por: Leung, Kenneth, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f3s6k5mcp4i2hgabmct6b320am